Source: Annual Congress 2013 –COPD: markers and inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sanzharovskaya, E. Budankova, A. Fisenko, E. Kuzin, E. Ustyuzhanina, G. Chernyavskaya, G. Chernogoryuk (Tomsk, Russian Federation). Bullous emphysema and severe COPD in acetylated opium users. Eur Respir J 2013; 42: Suppl. 57, 3298

Member's Comments

No comment yet.

Related content which might interest you: Different response of lung tissue to intravenous acetylated opium Source: International Congress 2015 – Different data in COPD Year: 2015 Features of systemic inflammation in patients with stable COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Factors associated with exacerbation in a general practitioners’-based Swiss chronic obstructive pulmonary disease (COPD) cohort Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Local and systemic inflammation in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD markers Year: 2014 Emphysematous phenotype is an independent predictor for frequent exacerbation of chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD Year: 2014 COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Inflammation biomarkers of lung tissue damage in acute exacerbation of COPD patients Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Exacerbations in patients with chronic obstructive lung disease (COPD) and concomitant asthma Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014 Insulin resistance, lung function and exacerbation rate in chronic obstructive lung disease Source: International Congress 2015 – Monitoring airway diseases with lung function tests Year: 2015 Endothelial dysfunction and systemic inflammation in different COPD phenotypes Source: International Congress 2014 – COPD physiopathology Year: 2014 Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Pulmonary rehabilitation in COPD and other chronic lung diseases Source: International Congress 2015 – Functional capacity, exercise and pulmonary rehabilitation in chronic lung diseases Year: 2015 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations Source: Annual Congress 2013 –Investigating COPD in longitudinal studies Year: 2013 Midrange-proadrenomedullin in stable state predicts severe exacerbation of COPD Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Obesity and impairments in chronic obstruction pulmonary disease (COPD) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Evaluation of vitamin D levels in COPD and its correlation with disease severity and frequency of exacerbations Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Distinguishing features of pneumonia and exacerbations in COPD Source: International Congress 2015 – Prognostic factors in pneumonia: from clinical observations to experimental models Year: 2015 Impact of bronchiectasis on the course of COPD Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016